(Q46749965)

24 December 2017

title

Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy (English)

1 reference

24 December 2017

author

Alessandro Sciarra

series ordinal

2

1 reference

24 December 2017

Vincenzo Gentile

series ordinal

3

1 reference

24 December 2017

author name string

Franco Di Silverio

series ordinal

1

1 reference

24 December 2017

language of work or name

English

0 references

publication date

15 February 2008

1 reference

24 December 2017

published in

Urology

1 reference

24 December 2017

volume

71

1 reference

24 December 2017

issue

5

1 reference

24 December 2017

page(s)

947-951

1 reference

24 December 2017

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Intermittent endocrine therapy for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Intermittent endocrine therapy of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Distribution of Inflammation, Pre-Malignant Lesions, Incidental Carcinoma in Histologically Confirmed Benign Prostatic Hyperplasia: A Retrospective Analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Cyclooxygenase-1 and -2 isoenzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Cyclooxygenase-2 and prostate carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Natural history of progression after PSA elevation following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

EAU guidelines on prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.033

10.1016/J.UROLOGY.2007.09.033

7 January 2021

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

18279940

1 reference

24 December 2017